Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve ...
Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to its first fully ...
Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.
With nationwide availability now underway, twiist reaches a meaningful milestone in Sequel’s mission to empower the diabetes community with more choice and a more personalized, customizable AID ...
Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.
Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Insulet (NasdaqGS:PODD) has launched its Omnipod 5 Automated ...
Fully Closed-Loop System Feasibility Study to be presented at Insulet Symposium and in e-Poster during ATTD 2026 Real World Evidence of Settings Optimization in Omnipod 5 Users will also be shared ...
Insulet Corporation will report fourth-quarter and full-year 2025 financial results on Wednesday, February 18, before the market opens, as investors assess whether the diabetes device maker can ...
OLYMPIA, Wash. — For Aaron Ping, a debate unfolding in Olympia is deeply personal. At home, he still flips through photos of his son Avery: mountain biking with friends, hiking outdoors, playing with ...
Combining private sanctuaries with data-driven care, MUA'H empowers Corporate HR to proactively predict and manage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results